Pre-clinical studies more...human

We provide a clear and detailed picture of the effects of your compounds on neuronal physiology, from circuits down to single ion channels.

Recording from human cells at preclinical stages provides a unique opportunity to optimize compounds' selection and drastically limit the risk of failure.

Human iPSCs-derived neurons

Animal-to-human data translation is particularly poor in CNS-related pharma development.

We propose to use human neurons at preclinical stages to  ensure data reliability an limit the risk of failure.

​

• IPSC-derived neurons are a relevant model in the assessment of safety and efficacy profiles of compounds.

​

• In some cases, the cells may come from patient carrying a specific mutation of interest for several pathologies.

​

• IPSCs can be differentiated into the most comon cell types (glutamatergic, gabaergic, dopaminergic, motor etc.)

​

• Patch-clamp recordings do not take longer than on tissues from rodents.

​

• Results become far more predictive.

Human acute slices

As for human neuronal cultures, human acute slices are powerful in limiting the risk of failure at later stages. They differ in the approach and present different advantages.

​​

​

• Acute slices contain intact circuits including all endogenous cell types.

​

• Tissues are obtained directly during or after surgery and quickly transferred to a recording chamber.

​

​

​

Rodent acute slices

We provide dissociated cultures as well as acute slice recordings from rodents. These easy-to-use preparations present various advantages.

​

• All circuits are intact and all cell types are present.

​

• Alteration of circuit-specific phenomena can be studied: plasticity, gamma-oscillations, epilepsy etc.

• Transgenic mouse models reliably mimic human pathologies.

​

• Precise manipulations (e.g. cell-type-specificity, knock-out, optogenetics etc.) can easily be achieved by employing transgenic animals.